leadf
logo-loader
viewTempo Therapeutics

Tempo Therapeutics entering into clinical studies in 2020 with synthetic tissue repair material

Tempo Therapeutics Inc Founder Westbrook Weaver sat down with Proactive at the 2019 BIO Investor Forum.

Tempo is a privately-held California-based company that develops cell-free and biologic-free physical material scaffolds for tissue repair. It's synthetic material can be injected into a damaged area of tissue that's not recognized as foreign by the immune system.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment...

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the...

3 hours, 28 minutes ago

2 min read